Models of metastasis in drug discovery

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

By definition, animal models provide only an approximation of clinical reality. One reason for this, for example, is that although metastases are the primary cause of mortality from neoplasia, by are rarely considered a target in drug discovery and development. Due to the impact of metastasis on clinical disease, we posit that metastasis should be considered in drug discovery, in addition, to more traditional biologic concepts, including drug pharmacology and toxicity. Drug discovery and developmental studies can incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogeneic) with their inherent host-tumor microenvironmental interactions, in addition to confirmatory autochthonous and/or genetically engineered models (GEMs). This requires a rational and hierarchical approach using models of metastatic disease optimally using resected, orthotopic primary tumors and clinically relevant outcome parameters. In this chapter, we provide protocols for models of metastasis that can be used in translational and drug discovery studies.

Original languageEnglish (US)
Title of host publicationMouse Models for Drug Discovery
Subtitle of host publicationMethods and Protocols
EditorsGabriele Proetzel, Michael Wiles
Pages215-233
Number of pages19
DOIs
StatePublished - Dec 1 2010

Publication series

NameMethods in Molecular Biology
Volume602
ISSN (Print)1064-3745

Fingerprint

Drug Discovery
Neoplasm Metastasis
Neoplasms
Drug-Related Side Effects and Adverse Reactions
Animal Models
Pharmacology
Mortality

Keywords

  • Metastasis
  • autochthonous tumors
  • genetically engineered tumor models
  • orthotopic tumors
  • spontaneous metastasis

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Talmadge, J. E. (2010). Models of metastasis in drug discovery. In G. Proetzel, & M. Wiles (Eds.), Mouse Models for Drug Discovery: Methods and Protocols (pp. 215-233). (Methods in Molecular Biology; Vol. 602). https://doi.org/10.1007/978-1-60761-058-8_13

Models of metastasis in drug discovery. / Talmadge, James E.

Mouse Models for Drug Discovery: Methods and Protocols. ed. / Gabriele Proetzel; Michael Wiles. 2010. p. 215-233 (Methods in Molecular Biology; Vol. 602).

Research output: Chapter in Book/Report/Conference proceedingChapter

Talmadge, JE 2010, Models of metastasis in drug discovery. in G Proetzel & M Wiles (eds), Mouse Models for Drug Discovery: Methods and Protocols. Methods in Molecular Biology, vol. 602, pp. 215-233. https://doi.org/10.1007/978-1-60761-058-8_13
Talmadge JE. Models of metastasis in drug discovery. In Proetzel G, Wiles M, editors, Mouse Models for Drug Discovery: Methods and Protocols. 2010. p. 215-233. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-60761-058-8_13
Talmadge, James E. / Models of metastasis in drug discovery. Mouse Models for Drug Discovery: Methods and Protocols. editor / Gabriele Proetzel ; Michael Wiles. 2010. pp. 215-233 (Methods in Molecular Biology).
@inbook{af9ff29519a2467abc7c2f90d3071963,
title = "Models of metastasis in drug discovery",
abstract = "By definition, animal models provide only an approximation of clinical reality. One reason for this, for example, is that although metastases are the primary cause of mortality from neoplasia, by are rarely considered a target in drug discovery and development. Due to the impact of metastasis on clinical disease, we posit that metastasis should be considered in drug discovery, in addition, to more traditional biologic concepts, including drug pharmacology and toxicity. Drug discovery and developmental studies can incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogeneic) with their inherent host-tumor microenvironmental interactions, in addition to confirmatory autochthonous and/or genetically engineered models (GEMs). This requires a rational and hierarchical approach using models of metastatic disease optimally using resected, orthotopic primary tumors and clinically relevant outcome parameters. In this chapter, we provide protocols for models of metastasis that can be used in translational and drug discovery studies.",
keywords = "Metastasis, autochthonous tumors, genetically engineered tumor models, orthotopic tumors, spontaneous metastasis",
author = "Talmadge, {James E}",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/978-1-60761-058-8_13",
language = "English (US)",
isbn = "9781607610571",
series = "Methods in Molecular Biology",
pages = "215--233",
editor = "Gabriele Proetzel and Michael Wiles",
booktitle = "Mouse Models for Drug Discovery",

}

TY - CHAP

T1 - Models of metastasis in drug discovery

AU - Talmadge, James E

PY - 2010/12/1

Y1 - 2010/12/1

N2 - By definition, animal models provide only an approximation of clinical reality. One reason for this, for example, is that although metastases are the primary cause of mortality from neoplasia, by are rarely considered a target in drug discovery and development. Due to the impact of metastasis on clinical disease, we posit that metastasis should be considered in drug discovery, in addition, to more traditional biologic concepts, including drug pharmacology and toxicity. Drug discovery and developmental studies can incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogeneic) with their inherent host-tumor microenvironmental interactions, in addition to confirmatory autochthonous and/or genetically engineered models (GEMs). This requires a rational and hierarchical approach using models of metastatic disease optimally using resected, orthotopic primary tumors and clinically relevant outcome parameters. In this chapter, we provide protocols for models of metastasis that can be used in translational and drug discovery studies.

AB - By definition, animal models provide only an approximation of clinical reality. One reason for this, for example, is that although metastases are the primary cause of mortality from neoplasia, by are rarely considered a target in drug discovery and development. Due to the impact of metastasis on clinical disease, we posit that metastasis should be considered in drug discovery, in addition, to more traditional biologic concepts, including drug pharmacology and toxicity. Drug discovery and developmental studies can incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogeneic) with their inherent host-tumor microenvironmental interactions, in addition to confirmatory autochthonous and/or genetically engineered models (GEMs). This requires a rational and hierarchical approach using models of metastatic disease optimally using resected, orthotopic primary tumors and clinically relevant outcome parameters. In this chapter, we provide protocols for models of metastasis that can be used in translational and drug discovery studies.

KW - Metastasis

KW - autochthonous tumors

KW - genetically engineered tumor models

KW - orthotopic tumors

KW - spontaneous metastasis

UR - http://www.scopus.com/inward/record.url?scp=77449131744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449131744&partnerID=8YFLogxK

U2 - 10.1007/978-1-60761-058-8_13

DO - 10.1007/978-1-60761-058-8_13

M3 - Chapter

SN - 9781607610571

T3 - Methods in Molecular Biology

SP - 215

EP - 233

BT - Mouse Models for Drug Discovery

A2 - Proetzel, Gabriele

A2 - Wiles, Michael

ER -